The initial drug therapy for acute coronary syndrome (ACS) starts with aspirin, given as a chewed loading dose of 162 to 325 mg as soon as possible after symptoms begin. From there, several additional medications are layered on rapidly: a second antiplatelet drug, an anticoagulant, a high-intensity statin, and supportive treatments like beta blockers and nitroglycerin. The specific combination depends on whether the event is a STEMI (complete blockage) or NSTE-ACS (partial blockage), but the core drug classes are the same.
Aspirin: The First Drug Given
Aspirin is the single most important initial medication. The 2025 ACC/AHA guidelines recommend a loading dose of 162 to 325 mg given as early as possible, regardless of whether the patient will later undergo a catheterization procedure or be managed with medications alone. The tablet should be non-enteric coated and chewed rather than swallowed whole, because chewing breaks it down faster and produces antiplatelet effects within minutes instead of the 30 to 60 minutes a swallowed pill takes.
Second Antiplatelet Drug (P2Y12 Inhibitor)
Aspirin alone isn’t enough. A second antiplatelet agent from a different drug class is added to block another pathway platelets use to form clots. Three options are used in practice, each with a different loading dose:
- Ticagrelor: 180 mg loading dose. Works faster and more consistently than clopidogrel. Suitable for both STEMI and NSTE-ACS.
- Prasugrel: 60 mg loading dose. Also more potent than clopidogrel, but typically reserved for patients going to catheterization and generally avoided in patients with prior stroke or who are over 75 or under 60 kg due to bleeding risk.
- Clopidogrel: 300 mg or 600 mg loading dose. The oldest of the three and less consistently effective because of genetic variability in how people metabolize it. Often used when ticagrelor or prasugrel aren’t appropriate.
The choice between these three depends on the type of ACS, whether a procedure is planned, bleeding risk, and patient-specific factors. Ticagrelor and prasugrel are generally preferred over clopidogrel when there are no contraindications.
Anticoagulation to Prevent Clot Growth
While antiplatelet drugs stop new platelets from clumping, an anticoagulant is also started to prevent the existing clot from growing. This is given by injection or IV rather than by mouth.
Unfractionated heparin (UFH) is the most common choice, especially when a catheterization procedure is planned. The dose is weight-based: a bolus of 60 to 70 units per kilogram (up to 5,000 units), followed by a continuous IV drip. During a catheterization procedure, the bolus is higher, typically 70 to 100 units per kilogram.
Enoxaparin is an alternative, given as a subcutaneous injection at 1 mg/kg twice daily. It’s commonly used in NSTE-ACS when patients are being managed without an immediate procedure.
Fondaparinux is a third option that has shown advantages in NSTE-ACS specifically. In the large OASIS 5 trial of over 20,000 patients, fondaparinux (2.5 mg once daily subcutaneously) reduced major bleeding by 50% and mortality by 17% compared to enoxaparin. European guidelines in particular favor fondaparinux for NSTE-ACS patients not heading to immediate catheterization because of this lower bleeding risk.
High-Intensity Statin Therapy
A high-intensity statin is started as soon as the patient can take oral medication, and current evidence supports giving it before discharge or within the first couple of days. Some centers give a loading dose of 80 mg atorvastatin before a catheterization procedure, though starting it anytime in the first 48 hours appears equally effective.
The statin isn’t just about cholesterol. In the acute phase of a heart attack, statins help stabilize the ruptured plaque, reduce inflammation in the artery wall, and improve the function of the blood vessel lining. These effects begin before any meaningful change in cholesterol levels occurs, which is why early initiation matters. There is no reason to delay statin therapy once a patient with ACS can swallow pills.
Beta Blockers Within 24 Hours
Oral beta blockers are recommended within the first 24 hours for both STEMI and NSTE-ACS. These drugs slow the heart rate and lower blood pressure, which reduces the heart muscle’s demand for oxygen and limits the size of the damage zone.
Beta blockers are withheld if the patient shows signs of heart failure, has a low cardiac output, is at increased risk for cardiogenic shock, has significant heart rhythm conduction problems (like second- or third-degree heart block), or has active asthma or reactive airway disease. The key point is that beta blockers are given by mouth, not IV, in the initial period. IV beta blockers in the first hours carry a higher risk of causing dangerous drops in blood pressure.
Nitroglycerin for Chest Pain
Nitroglycerin is given to relieve ongoing chest pain by dilating blood vessels and improving blood flow to the heart. It can be administered as a sublingual tablet or spray initially, then as a continuous IV drip for persistent pain.
There is one critical scenario where nitroglycerin is avoided: right ventricular infarction. In this type of heart attack (which affects the right side of the heart), the right ventricle depends heavily on adequate blood return. Nitroglycerin reduces that blood return by dilating veins, which can cause a severe and sudden drop in blood pressure and cardiac output. Nitroglycerin is also avoided in patients who have taken certain erectile dysfunction medications within the prior 24 to 48 hours, and in patients whose systolic blood pressure is already below 90 mmHg.
Why Morphine Is Used Cautiously
Morphine has traditionally been given for severe chest pain that doesn’t respond to nitroglycerin, but its role has become more complicated. Research shows that morphine activates receptors in the gut that slow down digestion and reduce absorption of oral medications. This directly interferes with the P2Y12 inhibitors (ticagrelor, prasugrel, clopidogrel) that are critical in the first hours of treatment.
The effect is significant. One hour after morphine is given, platelet reactivity increases by roughly 59 units compared to patients not given morphine, meaning the antiplatelet drugs are working less effectively. At two hours, the gap widens further to about 68 units. This creates a vulnerable window during the exact period when preventing clot formation matters most. Because of this, morphine is now reserved for pain that truly cannot be controlled by other means, rather than being given routinely.
How the Drugs Work Together
The logic behind ACS drug therapy is layered defense. The ruptured plaque inside a coronary artery creates a surface that aggressively attracts platelets and triggers the clotting cascade. Aspirin blocks one platelet activation pathway. The P2Y12 inhibitor blocks a second. The anticoagulant disrupts the clotting cascade itself. Together, these three drug classes attack clot formation from multiple angles simultaneously.
Meanwhile, nitroglycerin and beta blockers reduce the heart’s workload and oxygen demand, limiting damage to the heart muscle during the time it takes to restore blood flow. The statin stabilizes the plaque that caused the problem in the first place and dampens the inflammatory response that could trigger further plaque rupture. Each drug has a distinct job, and the combination is what gives patients the best chance of preserving heart function and surviving the event.